NTRB 最新10-Q变化
将 NTRB 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-09-04 与上一份 10-Q · 2026-06-11
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +1 | −23 | 0 | 0 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 4 |
| 法律诉讼 | 文字有新增/删除 | +60 | −19 | ~27 | 39 |
| 风险因素 | 无段落级文字变化 | 0 | 0 | 0 | 21 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-09-04
Item 3 Quantitative and Qualitative Disclosures about Market Risk 24
相对上期删除的文字 · 来源:10-Q · 2026-06-11
This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify …
Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcom…
We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this …
Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary …
The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Thera…
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-09-04
Number of Number of Paid In Comprehensive Accumulated Treasury
Total shares Amount shares Amount Capital Income(Loss) Deficit Stock
Number of Number of Paid In Comprehensive Accumulated Treasury
Total shares Amount shares Amount Capital Income(Loss) Deficit Stock
Proceeds from the exercise of employee stock options - 44,206
相对上期删除的文字 · 来源:10-Q · 2026-06-11
Net loss per share attributable to common stockholders - basic and diluted $(0.10) $(0.12)
Weighted average common shares outstanding - basic and diluted 12,155,983 11,125,800
Proceeds from sale of common stock and exercise of warrants - -
as of and for the Three Months Ended April 30, 2026 and 2025
The Company’s revenues include significant concentration from a limited number of customers. For the three months ended April 30, 2026, Customer A, Customer B, Customer C, and Customer D accounted for approximately 25%, 20%, 14%, and 10% of the Company’s total consolidated revenues.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议